Alphyn Biologics reports positive results from the first cohort of a Phase 2a trial for the treatment of mild to moderate atopic dermatitis

Alphyn Biologics, a clinical-stage dermatology company that develops the first multi-target therapeutic, announced January 5 positive results
in its Phase 2a clinical trial for the treatment of mild to moderate atopic dermatitis (AD) topical AB-101a.
The trial met all primary endpoints, showing the potential
of AB-101a as an effective and safe treatment for AD.

This randomized, solvent-controlled, double-blind trial evaluated AB-101a regimens at multiple sites using a standard evaluation scale for AD
.
The trial, conducted in Australia, enrolled 41 AD patients and was evaluated
four weeks after treatment was started.

Dr Stephen Shumack, Clinical Associate Professor of Dermatology at the University of Sydney and Principal Investigator of St George's Centre for Dermatology and Skin Cancer, said: "As a physician treating 15% of patients in this clinical trial, I am encouraged
by the results of AB-101a.
I look forward to future trials and to learning more about the potential patient benefits
of AB-101a.
" "

Neal Koller, CEO of Alphyn, said: "Atopic dermatitis is a often debilitating condition in which mild to moderate patients are severely affected by the associated symptoms, but existing treatments come with side effects and safety concerns
.
We are excited about the results of this trial and look forward to the results
of our current infectious AD cohort.
We plan to further investigate AB-101a through a Phase 2b/3 trial this year, along with Series B funding
.
"

Alphyn plans to present the full results of the trial at a scientific conference and submit a paper for publication in a peer-reviewed journal
.
A second cohort of subjects in the Phase 2a clinical trial is recruiting
.
The cohort was studied on AB-101a's unique ability to treat components of AD infection in AD patients with bacterial infections, including targeting Staphylococcus aureus ("Staphylococcus") and methicillin-resistant Staphylococcus aureus MRSA
.
Alphyn expects AB-101a to be effective in the treatment of both non-infectious AD and infectious AD
.
AB-101a will provide AD patients and physicians with a comprehensive, safe, and convenient treatment option
.

The AB-101a was developed
using Alphyn's proprietary AB-101 platform.
The platform contains a wide range of bioactive compounds, resulting in multiple mechanisms
of action that address multiple issues related to any target disease.
Because of the strong safety of its AB-101 platform, Alphyn has initiated a clinical trial program for AB-101a
.